Affective Disorders, PsychoticPhase 3NCT00867360
Treatment of Psychotic Major Depression With Mifepristone
A Phase 3 study testing Mifepristone (RU-486) in people with Affective Disorders, Psychotic and Depressive Disorder, run by Stanford University at 1 site in United States.
Trial summary
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression. Read more about this study
- Who is it for?
- Ages 21 to 85 years
- Conditions the study is for
- Affective Disorders, Psychotic, Depressive Disorder
- What is being tested?
- Mifepristone (RU-486)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2005to May 2009
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Inclusion Criteria:Inclusion criteria for PMD (individuals with Psychotic Major Depression) are as follows:
- DSM IV diagnosis of Major Depressive Disorder with psychotic features, Bipolar II Disorder with psychotic features in a major depressive episode.
- 21-item HAM-D score greater than or equal to 21.
- Thase Core Endogenomorphic Scale score greater than or equal to 6 on the items included in the 21-item HDRS.
- Between 21 - 85 years of age.
- Female patients of child bearing capacity with Psychotic Depression receiving treatment with mifepristone are required to use a double-barrier method of contraception or abstinence for the entire duration of the study as well as for thirty days after the last dose of Mifepristone is taken.
- If currently taking antipsychotic, antidepressant, anticonvulsant, and/or mood-stabilizing medications, must be stable on the medication for at least one-week prior to entering the study.
- Pre-existing (current) primary treating psychiatrist for subjects with psychotic features.
- Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Primary pre-existing chronic Obsessive-Compulsive Disorder(OCD) will be an exclusion criteria. Exclusion Criteria:Exclusion criteria for PMDs are as follows:
- ECT in the 6 months prior to the study. 2. Abuse of drugs or alcohol in the 6 months prior to study. 3. Unstable or untreated hypertension, cardiovascular disease. 4. If participating in the blood draw portion of the protocol, endocrine disorders are exclusionary. 5. Use of additional prescription medications, street drugs, or alcohol during the week before the study. 6. Previous mifepristone failure or non-response. 7. Any Axis II diagnosis or traits which would make participation in the study difficult. 8. Current pregnancy or lactation.
Trial locations and contacts
1 site in 1 country.
United States1 site
Stanford University School of Medicine
Stanford, California, 94305
About this study
Official title: Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.
This study is conducted in conjunction with an observational study "Clinical and Biological Characteristics of Psychotic Depression".
Read the detailed description
Eligibility Procedures: Before entering the study and prior to any other procedures, you will be asked to read and sign this consent form. To determine if you are eligible for our study, you will then have a general medical (including menstrual cycle history on female patients) and psychiatric history taken, a physical examination, your vital signs (blood pressure, pulse), height, weight and waist/hip ratio will be measured, as well as various psychiatric evaluations will be conducted.
You will be randomly (by chance) assigned to receive mifepristone or placebo (an inactive substance). Half of the participants in this research study will receive placebo, and half will receive mifepristone. Neither you nor your study doctor will know which of the two you are receiving. Treatment will begin in the morning of Treatment Day 1 and conclude on Treatment Day 8 for a total treatment period of 8 days. You will take the medication once a day in the morning. The dose was originally 600 mg but was changed to 1200 mg per day after the 4th patient. You will not be able to take any new medications (other than the study drug) or make changes to your current medications while participating in this part of the study unless ordered by the study physician.
On treatment Day 1, you will come to our office for an interview and we will evaluate your mood and other psychiatric symptoms. Additionally, we will take your vital signs and draw blood to administer clinical laboratory tests. You will meet with the study physician and will then be given 4-days of medication to take home with you and self-administer each morning.
On Treatment Day 4, you will come back to our office. We will evaluate your mood, take your vital signs and you will meet with the study physician. It is important that you discuss with your study physician or the research study staff all unpleasant or unusual symptoms that you may experience. Any positive effects that are experienced should be discussed as well. You will be given an additional 4-days of medication to take home with you to self-administer each morning.
On Treatment Day 8, we will re-evaluate your mood, take your vital signs and repeat the blood and urine lab tests. You will also meet with the study physician to discuss any side effects. If you are participating in the blood draw portion of this study, you will be admitted to the GCRC on this day for an overnight stay. At 2pm on Treatment Day 8, you will have an IV line inserted into one arm for hourly blood samples from 2pm, 4pm, then 6pm until 9am on Treatment Day 9. At 9am on treatment Day 9, 10 mls of blood will be taken for Mifepristone concentration. A total of 82mls (approximately 5.5 tablespoons) of blood will be drawn. You will be discharged from the GCRC following breakfast.
On Treatment Day 15, we will re-evaluate your mood and you will meet with the study physician to discuss any side effects.
On Treatment Day 22, you will be readmitted to the GCRC, where nurses will take your vitals signs and repeat the clinical laboratory tests. We will also reevaluate your mood, and you will meet with the study physician to discuss any side effects. If you have participated in portions or all of the baseline protocol (protocol # 13088) you will repeat neuropsychological, MRI and blood draw procedures accordingly. If you did not participate in the baseline protocol, you will be assessed for safety and discharged.
You will have another functional MRI (a picture taken of your brain using a magnet while you are administered a series of tasks). This MRI scan procedure will take approximately 1 hour. You will be given a series of neuropsychological tests to assess your memory and concentration. You will be asked to complete several questionnaires during your hospital stay. These questionnaires ask for your views about your personality, your childhood, your quality of life, your mood and a variety of aspects of your daily functioning. The questionnaires may be completed anytime during your overnight stay and will take about 2.5 hours to finish. On treatment Day 22, you will have an IV line inserted into one arm for hourly blood samples taken at 2pm, 4pm and then hourly from 6pm to 9am. A total of 72 ml's (approximately 5 tablespoons) of blood will be drawn.
At 2pm on Treatment Day 23, you will have another IV line placed in your arm to draw hourly blood samples used for the measure of ACTH and cortisol. These blood samples are taken in small amounts (approximately 1 teaspoon) and will be collected at 2pm and then on the hour, every hour, starting at 3pm and ending at 7pm, then every 30 minutes until 12pm. At 3pm, you will be given 0.5mg (five 0.1mg tablets) of Fludrocortisone. At 4pm, 10 mls of blood will be taken for Mifepristone concentration. Following the last blood draw at 12pm, a blood sample will be taken for clinical laboratory assessment to ensure your safety following Fludrocortisone administration. A total of 76ml's (approximately 5 tablespoons) of blood will be drawn. The IV line will then be removed and your vital signs will be assessed.
The following morning, the study physician will contact the experimental pharmacy and find out whether you have received placebo (no medication) or mifepristone. If you have been treated with mifepristone, this will mark the end of your study participation and the research coordinator will discuss follow-up assessments with you. The follow up assessments will be as follows: mood assessments will be performed via phone on weeks 1 and 2 and months 1, 3, 6, and 12 after completion of the study. These assessments will take a maximum of 1 hour to complete. The physician will also confirm your continued care and treatment with your primary treating psychiatrist. You will then be discharged from the GCRC and the hospital.
If you have been on the placebo, you will be offered an 8-day open-label trial of mifepristone.
- Being tested
- Mifepristone (RU-486), Placebo
- Medical subject headings
- Affective Disorders, Psychotic, Depressive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mifepristone (RU-486)Drug
PlaceboDrug
Placebo medication
| Study group | Role | What they receive |
|---|---|---|
| Mifepristone | Experimental | Receive mifepristone for 8 days Receives: Drug: Mifepristone (RU-486) |
| Placebo | Placebo comparator | Receive placebo rather than mifepristone Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Psychotic Symptoms Subscale (PSS) of the Brief Psychiatric Rating Scale (BPRS)
The BRPS is a rating scale of various psychiatric symptoms. Each item is rated on a scale of 1 to 7, with 1 being not present. The PSS is the sum of 4 items from the BPRS, which indicates the level of positive psychotic symptoms.. Thus, the range for the PSS is 4 to 28, with higher scores indicating greater levels of positive psychotic symptoms.
For ease of interpretation, the sum of the PSS then has 4 items subtracted so that a score of 0 (instead of 4) indicates that there are no psychotic symptoms. In doing this, the range for the PSS becomes 0 to 24), with larger values indicating more positive psychotic symptoms.
The measure is the change score of PSS total day 1 less PSS total Day 9. 0 indicates no change, where as positive numbers indicate a decrease in psychotic symptoms.
Measured: baseline to day 9
Change in Mean Cortisol Level
The reported value is the difference in mean evening cortisol from baseline to Day 9 The mean evening cortisol is calculated from the hourly cortisol value taken from 1800 hrs to 0100 hrs for both time points. The outcome measure is the difference of mean evening cortisol from Day 9 less the mean evening cortrisol from baseline. Negative values indicate a reduction in cortisol levels at Day 9, whereas positive values indicate an increase in cortisol at Day 9. Serum cortisol levels are reported in ug/dL
Measured: Day 1 to Day 9 difference
Secondary outcomes (1)
% Change in Mean Evening Pre- and Post- Florinef Cortisol After Treatment With Either Mifepristone or Placebo
Time 1 (baseline) = Difference in cortisol level from Day 1 (pre-florinef mean evening cortisol) at Baseline less Day 2 (post-florinef mean evening cortisol) at baseline
Time 2 (post- mife or placebo treatment) = Difference in cortisol level from Day 22 (pre-florinef mean evening cortisol) and Day 23 (post-florinef mean evening cortisol level).
All measurements were the percent change in mean cortisol level from 6 pm to 10 pm. Cortisol levels are expressed as ug/dL
Percent change in cortisol decrease between Time 2 and Time 1 post florinef should be greater with mifepristone than placebo, reflecting enhanced mineralocorticoid receptor activity.
Measured: Day 23
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2009 (estimated)
- Study startAug 2005
- Primary completionMay 2009
- Study completionMay 2009
Why it stopped: Insufficient recruitment.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Affective Disorders, PsychoticStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alan Schatzberg, Stanford University
- Investigators
- Fredric B Kraemer, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00867360
- Sponsor's protocol ID
- SU-02262009-1838
- Status last verified
- Feb 2017
- First submitted
- 20 Mar 2009
- Last updated
- 4 Apr 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression
- ClinicalTrials.gov ID
- NCT00867360
- Acronym / sponsor ID
- SU-02262009-1838
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Insufficient recruitment.
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- Aug 2005
- Primary completion
- May 2009 (actual)
- Study completion
- May 2009 (actual)
- First posted
- 23 Mar 2009 (estimated)
- Results
- Posted 4 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.
This study is conducted in conjunction with an observational study "Clinical and Biological Characteristics of Psychotic Depression".
Detailed description
Eligibility Procedures: Before entering the study and prior to any other procedures, you will be asked to read and sign this consent form. To determine if you are eligible for our study, you will then have a general medical (including menstrual cycle history on female patients) and psychiatric history taken, a physical examination, your vital signs (blood pressure, pulse), height, weight and waist/hip ratio will be measured, as well as various psychiatric evaluations will be conducted.
You will be randomly (by chance) assigned to receive mifepristone or placebo (an inactive substance). Half of the participants in this research study will receive placebo, and half will receive mifepristone. Neither you nor your study doctor will know which of the two you are receiving. Treatment will begin in the morning of Treatment Day 1 and conclude on Treatment Day 8 for a total treatment period of 8 days. You will take the medication once a day in the morning. The dose was originally 600 mg but was changed to 1200 mg per day after the 4th patient. You will not be able to take any new medications (other than the study drug) or make changes to your current medications while participating in this part of the study unless ordered by the study physician.
On treatment Day 1, you will come to our office for an interview and we will evaluate your mood and other psychiatric symptoms. Additionally, we will take your vital signs and draw blood to administer clinical laboratory tests. You will meet with the study physician and will then be given 4-days of medication to take home with you and self-administer each morning.
On Treatment Day 4, you will come back to our office. We will evaluate your mood, take your vital signs and you will meet with the study physician. It is important that you discuss with your study physician or the research study staff all unpleasant or unusual symptoms that you may experience. Any positive effects that are experienced should be discussed as well. You will be given an additional 4-days of medication to take home with you to self-administer each morning.
On Treatment Day 8, we will re-evaluate your mood, take your vital signs and repeat the blood and urine lab tests. You will also meet with the study physician to discuss any side effects. If you are participating in the blood draw portion of this study, you will be admitted to the GCRC on this day for an overnight stay. At 2pm on Treatment Day 8, you will have an IV line inserted into one arm for hourly blood samples from 2pm, 4pm, then 6pm until 9am on Treatment Day 9. At 9am on treatment Day 9, 10 mls of blood will be taken for Mifepristone concentration. A total of 82mls (approximately 5.5 tablespoons) of blood will be drawn. You will be discharged from the GCRC following breakfast.
On Treatment Day 15, we will re-evaluate your mood and you will meet with the study physician to discuss any side effects.
On Treatment Day 22, you will be readmitted to the GCRC, where nurses will take your vitals signs and repeat the clinical laboratory tests. We will also reevaluate your mood, and you will meet with the study physician to discuss any side effects. If you have participated in portions or all of the baseline protocol (protocol # 13088) you will repeat neuropsychological, MRI and blood draw procedures accordingly. If you did not participate in the baseline protocol, you will be assessed for safety and discharged.
You will have another functional MRI (a picture taken of your brain using a magnet while you are administered a series of tasks). This MRI scan procedure will take approximately 1 hour. You will be given a series of neuropsychological tests to assess your memory and concentration. You will be asked to complete several questionnaires during your hospital stay. These questionnaires ask for your views about your personality, your childhood, your quality of life, your mood and a variety of aspects of your daily functioning. The questionnaires may be completed anytime during your overnight stay and will take about 2.5 hours to finish. On treatment Day 22, you will have an IV line inserted into one arm for hourly blood samples taken at 2pm, 4pm and then hourly from 6pm to 9am. A total of 72 ml's (approximately 5 tablespoons) of blood will be drawn.
At 2pm on Treatment Day 23, you will have another IV line placed in your arm to draw hourly blood samples used for the measure of ACTH and cortisol. These blood samples are taken in small amounts (approximately 1 teaspoon) and will be collected at 2pm and then on the hour, every hour, starting at 3pm and ending at 7pm, then every 30 minutes until 12pm. At 3pm, you will be given 0.5mg (five 0.1mg tablets) of Fludrocortisone. At 4pm, 10 mls of blood will be taken for Mifepristone concentration. Following the last blood draw at 12pm, a blood sample will be taken for clinical laboratory assessment to ensure your safety following Fludrocortisone administration. A total of 76ml's (approximately 5 tablespoons) of blood will be drawn. The IV line will then be removed and your vital signs will be assessed.
The following morning, the study physician will contact the experimental pharmacy and find out whether you have received placebo (no medication) or mifepristone. If you have been treated with mifepristone, this will mark the end of your study participation and the research coordinator will discuss follow-up assessments with you. The follow up assessments will be as follows: mood assessments will be performed via phone on weeks 1 and 2 and months 1, 3, 6, and 12 after completion of the study. These assessments will take a maximum of 1 hour to complete. The physician will also confirm your continued care and treatment with your primary treating psychiatrist. You will then be discharged from the GCRC and the hospital.
If you have been on the placebo, you will be offered an 8-day open-label trial of mifepristone.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mifepristone | Experimental | Drug: Mifepristone (RU-486)Receive mifepristone for 8 days |
| Placebo | Placebo comparator | Drug: PlaceboReceive placebo rather than mifepristone |
Who may qualify
- Ages
- 21 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mifepristone (RU-486) | Drug | Mifepristone |
| PlaceboPlacebo medication | Drug | Placebo |
Primary outcome
Change in Psychotic Symptoms Subscale (PSS) of the Brief Psychiatric Rating Scale (BPRS)
Time frame: baseline to day 9
The BRPS is a rating scale of various psychiatric symptoms. Each item is rated on a scale of 1 to 7, with 1 being not present. The PSS is the sum of 4 items from the BPRS, which indicates the level of positive psychotic symptoms.. Thus, the range for the PSS is 4 to 28, with higher scores indicating greater levels of positive psychotic symptoms. For ease of interpretation, the sum of the PSS then has 4 items subtracted so that a score of 0 (instead of 4) indicates that there are no psychotic symptoms. In doing this, the range for the PSS becomes 0 to 24), with larger values indicating more positive psychotic symptoms. The measure is the change score of PSS total day 1 less PSS total Day 9. 0 indicates no change, where as positive numbers indicate a decrease in psychotic symptoms.
Change in Mean Cortisol Level
Time frame: Day 1 to Day 9 difference
The reported value is the difference in mean evening cortisol from baseline to Day 9 The mean evening cortisol is calculated from the hourly cortisol value taken from 1800 hrs to 0100 hrs for both time points. The outcome measure is the difference of mean evening cortisol from Day 9 less the mean evening cortrisol from baseline. Negative values indicate a reduction in cortisol levels at Day 9, whereas positive values indicate an increase in cortisol at Day 9. Serum cortisol levels are reported in ug/dL
1 secondary outcome
% Change in Mean Evening Pre- and Post- Florinef Cortisol After Treatment With Either Mifepristone or Placebo
Time frame: Day 23
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Affective Disorders, Psychotic
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Recruiting
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Schizophrenia Spectrum Disorders, Psychotic Affective Disorders
Active, not recruitingObservational study
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections
Severe Mental Illness, Inflammation
Recruiting
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Schizophrenia, Schizo Affective Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fredric B Kraemer principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Mifepristone (RU-486) in people with Affective Disorders, Psychotic and Depressive Disorder, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Psychotic Symptoms Subscale (PSS) of the Brief Psychiatric Rating Scale (BPRS) (time frame: baseline to day 9). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2017.